Results 31 to 40 of about 20,356 (205)
Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models
Objective Dysregulated type I interferon (IFN) signaling contributes to autoimmune myositis pathogenesis. We investigated the therapeutic effects of JAK inhibitors in two mouse models. We also examined how type I IFNs affect muscle vasculature. Methods Myositis was induced in major histocompatibility complex class I double transgenic ([TRE‐H‐2Kb (H ...
Rita Spathis +11 more
wiley +1 more source
Gastrointestinal perforation in patients with juvenile dermatomyositis has been reported as a life-threatening complication in the literature. However, effective treatment of juvenile dermatomyositis with gastrointestinal perforation remains challenging.
Xue-mei Xu +8 more
doaj +1 more source
Narrowband Intense Pulsed Light Treatment for Refractory Facial Rash Associated with Dermatomyositis
Yuxin Zheng, Suiqing Cai Department of Dermatology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, People’s Republic of ChinaCorrespondence: Suiqing Cai, Department of Dermatology, Zhejiang University School of Medicine ...
Zheng Y, Cai S
doaj
Objective Myositis‐specific autoantibodies guide the diagnosis and classification of idiopathic inflammatory myopathies, but current immunoassays vary in accuracy, particularly for autoantibodies associated with interstitial lung disease. To compare the performance of the luciferase immunoprecipitation systems (LIPS) assay with line blot and ...
Peter D. Burbelo +14 more
wiley +1 more source
BackgroundDermatomyositis is an idiopathic inflammatory myopathy and occurs as a paraneoplastic syndrome. Here, we report an unusual case of dermatomyositis that developed in a patient after the resection of thyroid cancer and breast cancer.
Miaomiao Yang, Jiannan Liu
doaj +1 more source
We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and ...
Ryosuke Imai +2 more
doaj +1 more source
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes +10 more
wiley +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz +13 more
wiley +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Dermatomyositis with subcutaneous edema is a rare process with few reported cases. We report a 63-year-old with lung cancer who presented with an erythematous skin rash and was found to have biopsyproven dermatomyositis.
Kevin Zarrabi +4 more
doaj +1 more source

